[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

EA201491281A1 - КОМПОЗИЦИЯ В ФОРМЕ СУХОГО ПОРОШКА, СОДЕРЖАЩАЯ КОРТИКОСТЕРОИД И β-АДРЕНЕРГИЧЕСКОЕ ЛЕКАРСТВЕННОЕ СРЕДСТВО, ДЛЯ ВВЕДЕНИЯ ИНГАЛЯЦИЕЙ - Google Patents

КОМПОЗИЦИЯ В ФОРМЕ СУХОГО ПОРОШКА, СОДЕРЖАЩАЯ КОРТИКОСТЕРОИД И β-АДРЕНЕРГИЧЕСКОЕ ЛЕКАРСТВЕННОЕ СРЕДСТВО, ДЛЯ ВВЕДЕНИЯ ИНГАЛЯЦИЕЙ

Info

Publication number
EA201491281A1
EA201491281A1 EA201491281A EA201491281A EA201491281A1 EA 201491281 A1 EA201491281 A1 EA 201491281A1 EA 201491281 A EA201491281 A EA 201491281A EA 201491281 A EA201491281 A EA 201491281A EA 201491281 A1 EA201491281 A1 EA 201491281A1
Authority
EA
Eurasian Patent Office
Prior art keywords
composition
dry powder
inhalation
introduction
powder containing
Prior art date
Application number
EA201491281A
Other languages
English (en)
Other versions
EA026267B1 (ru
Inventor
Элиза Монари
Анна Мария Кантарелли
Даниела Коккони
Ирене Паскуали
Original Assignee
КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47715987&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201491281(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. filed Critical КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А.
Publication of EA201491281A1 publication Critical patent/EA201491281A1/ru
Publication of EA026267B1 publication Critical patent/EA026267B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0001—Details of inhalators; Constructional features thereof
    • A61M15/0003—Details of inhalators; Constructional features thereof with means for dispensing more than one drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
    • A61M15/003—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using capsules, e.g. to be perforated or broken-up
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/009—Inhalators using medicine packages with incorporated spraying means, e.g. aerosol cans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/06—Solids
    • A61M2202/064—Powder

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Otolaryngology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Изобретение относится к композиции в форме сухого порошка, содержащей кортикостероид и β-адренергическое лекарственное средство в комбинации, способу ее изготовления и ее терапевтическому применению.
EA201491281A 2012-01-25 2013-01-23 Композиция в форме сухого порошка, содержащая кортикостероид и бета-адренергическое лекарственное средство, для введения ингаляцией EA026267B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12152392 2012-01-25
PCT/EP2013/051187 WO2013110632A1 (en) 2012-01-25 2013-01-23 Dry powder formulation comprising a corticosteroid and a beta-adrenergic for administration by inhalation

Publications (2)

Publication Number Publication Date
EA201491281A1 true EA201491281A1 (ru) 2014-12-30
EA026267B1 EA026267B1 (ru) 2017-03-31

Family

ID=47715987

Family Applications (2)

Application Number Title Priority Date Filing Date
EA201690187A EA031566B1 (ru) 2012-01-25 2013-01-23 Единичная лекарственная форма в форме композиции сухого порошка, применение единичной лекарственной формы и ингалятор сухого порошка, заполненный единичной лекарственной формой
EA201491281A EA026267B1 (ru) 2012-01-25 2013-01-23 Композиция в форме сухого порошка, содержащая кортикостероид и бета-адренергическое лекарственное средство, для введения ингаляцией

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EA201690187A EA031566B1 (ru) 2012-01-25 2013-01-23 Единичная лекарственная форма в форме композиции сухого порошка, применение единичной лекарственной формы и ингалятор сухого порошка, заполненный единичной лекарственной формой

Country Status (38)

Country Link
US (3) US10028964B2 (ru)
EP (7) EP3527196B1 (ru)
JP (1) JP6104282B2 (ru)
KR (3) KR101560288B1 (ru)
CN (2) CN104080444B (ru)
AR (1) AR089805A1 (ru)
AU (1) AU2013211656B2 (ru)
BR (1) BR112014017481A8 (ru)
CA (1) CA2862548C (ru)
CL (1) CL2014001966A1 (ru)
CO (1) CO7010836A2 (ru)
CY (1) CY1120684T1 (ru)
DK (6) DK3412277T3 (ru)
EA (2) EA031566B1 (ru)
ES (5) ES2938466T3 (ru)
FI (1) FI3412277T3 (ru)
GE (1) GEP201706767B (ru)
HK (1) HK1200021A1 (ru)
HR (5) HRP20221432T1 (ru)
HU (5) HUE060402T2 (ru)
IL (1) IL233784A0 (ru)
LT (5) LT3412277T (ru)
MA (1) MA35859B1 (ru)
MX (2) MX355729B (ru)
MY (1) MY165888A (ru)
NZ (1) NZ627837A (ru)
PE (1) PE20141703A1 (ru)
PH (1) PH12014501565A1 (ru)
PL (5) PL3527196T3 (ru)
PT (5) PT2806855T (ru)
RS (5) RS63759B1 (ru)
SG (1) SG11201404350PA (ru)
SI (2) SI3412277T1 (ru)
TN (1) TN2014000322A1 (ru)
TW (1) TWI559940B (ru)
UA (1) UA115543C2 (ru)
WO (1) WO2013110632A1 (ru)
ZA (1) ZA201405464B (ru)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20221432T1 (hr) * 2012-01-25 2023-01-06 Chiesi Farmaceutici S.P.A. Formulacija suhog praška koja sadrži antikolinergik, kortikosteroid i beta-adrenergik za davanje inhalacijom
PE20212110A1 (es) 2013-07-11 2021-11-04 Chiesi Farm Spa Formulacion en polvo seco que comprende un anticolinergico, un corticosteroide y un beta-adrenergico para administrar por inhalacion
UA118861C2 (uk) * 2013-12-06 2019-03-25 Оріон Корпорейшн Спосіб отримання сухих порошкових композицій для інгаляцій
WO2016055544A1 (en) 2014-10-08 2016-04-14 Eratech S.R.L. Composition comprising at least one dry powder obtained by spray drying to increase the stability of the formulation
WO2018059390A1 (zh) * 2016-09-29 2018-04-05 广东东阳光药业有限公司 药物组合物
MX2019012931A (es) * 2017-05-11 2020-01-20 Chiesi Farm Spa Proceso para preparar una formulacion de polvo seco que comprende un anticolinergico, un corticosteroide y un beta-adrenergico.
US11931368B2 (en) 2017-09-29 2024-03-19 Crititech, Inc. Glucocorticoid “nintedanib” particles and their use
EP3910324A1 (en) * 2018-08-07 2021-11-17 Norton (Waterford) Limited Application of raman spectroscopy for the manufacture of inhalation powders
ES2969709T3 (es) 2018-10-30 2024-05-22 Chiesi Farm Spa Aparato para administrar fármacos a pacientes ventilados mecánicamente
EP4034079A1 (en) 2019-09-24 2022-08-03 Chiesi Farmaceutici S.p.A. Novel carrier particles for dry powder formulations for inhalation
JP2023539073A (ja) 2020-08-14 2023-09-13 ノートン （ウォーターフォード） リミテッド プロピオン酸フルチカゾンと硫酸アルブテロールの吸入製剤
WO2023117967A1 (en) * 2021-12-21 2023-06-29 Chiesi Farmaceutici S.P.A. Dry powder formulations filled in an inhaler with improved resistance to humidity

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9501841D0 (en) * 1995-01-31 1995-03-22 Co Ordinated Drug Dev Improvements in and relating to carrier particles for use in dry powder inhalers
EP2266548B1 (de) * 1998-11-13 2020-05-20 Jagotec AG Trockenpulver zur inhalation
IT1309592B1 (it) * 1999-03-05 2002-01-24 Chiesi Farma Spa Particelle veicolo modificate da utilizzarsi nella preparazione diformulazioni farmaceutiche sotto forma di polimeri per inalazione e
PE20011227A1 (es) 2000-04-17 2002-01-07 Chiesi Farma Spa Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros
GB0015043D0 (en) 2000-06-21 2000-08-09 Glaxo Group Ltd Medicament dispenser
FI20002215A0 (fi) * 2000-10-06 2000-10-06 Orion Yhtymae Oyj Yhdistelmäpartikkelit
EP1658872B2 (en) 2002-07-31 2019-08-21 CHIESI FARMACEUTICI S.p.A. Powder inhaler
JO3102B1 (ar) * 2004-03-17 2017-09-20 Chiesi Framaceutici S P A صيغ صيدلانية لوسائل استنشاق بها مسحوق جاف تشتمل على مكون فعال بقوة منخفضة الجرعة
ES2257152B1 (es) * 2004-05-31 2007-07-01 Laboratorios Almirall S.A. Combinaciones que comprenden agentes antimuscarinicos y agonistas beta-adrenergicos.
EP1944018A1 (en) * 2007-01-10 2008-07-16 CHIESI FARMACEUTICI S.p.A. Micronised particles of low-dosage strength active agents for powder formulations for inhalation
EP1982709A1 (en) * 2007-04-19 2008-10-22 CHIESI FARMACEUTICI S.p.A. Use of a composition comprising formoterol and beclomethasone dipropionate for the prevention or treatment of an acute condition of asthma
WO2010097188A1 (en) * 2009-02-25 2010-09-02 Chiesi Farmaceutici S.P.A. Inhalation particles comprising a salt of carmoterol and a corticosteroid
EP2429495A4 (en) * 2009-05-15 2014-01-22 Shin Nippon Biomedical Lab Ltd INTRANASAL PHARMACEUTICAL COMPOSITIONS WITH ENHANCED PHARMACOKINETICS
GB0914240D0 (en) * 2009-08-14 2009-09-30 Breath Ltd Steroid solvates
SI2727582T1 (sl) * 2009-10-02 2016-05-31 Chiesi Farmaceutici S.P.A. Farmacevtske aerosolne formulacije formoterola in beklometazon dipropionata
AU2011234751B2 (en) * 2010-04-01 2016-03-17 Chiesi Farmaceutici S.P.A. Process for preparing carrier particles for dry powders for inhalation
EP2560611B1 (en) 2010-04-21 2018-01-03 Chiesi Farmaceutici S.p.A. "process for providing particles with reduced electrostatic charges"
HRP20221432T1 (hr) * 2012-01-25 2023-01-06 Chiesi Farmaceutici S.P.A. Formulacija suhog praška koja sadrži antikolinergik, kortikosteroid i beta-adrenergik za davanje inhalacijom
PE20212110A1 (es) * 2013-07-11 2021-11-04 Chiesi Farm Spa Formulacion en polvo seco que comprende un anticolinergico, un corticosteroide y un beta-adrenergico para administrar por inhalacion

Also Published As

Publication number Publication date
RS63761B1 (sr) 2022-12-30
UA115543C2 (uk) 2017-11-27
PH12014501565B1 (en) 2014-10-08
EP3412277B1 (en) 2022-12-14
CN105726548A (zh) 2016-07-06
PT2806855T (pt) 2018-09-28
US10028964B2 (en) 2018-07-24
PT3527199T (pt) 2022-11-08
HUE060402T2 (hu) 2023-02-28
MX2014008631A (es) 2014-08-21
BR112014017481A8 (pt) 2021-06-15
HRP20181550T1 (hr) 2018-11-30
KR20170116234A (ko) 2017-10-18
EA026267B1 (ru) 2017-03-31
SG11201404350PA (en) 2014-08-28
PT3527197T (pt) 2022-10-26
KR20140114374A (ko) 2014-09-26
DK3527196T3 (da) 2022-10-24
KR20150089093A (ko) 2015-08-04
EA031566B1 (ru) 2019-01-31
EA201690187A1 (ru) 2016-05-31
CY1120684T1 (el) 2019-12-11
EP3527199B1 (en) 2022-09-07
GEP201706767B (en) 2017-11-10
US20150164915A1 (en) 2015-06-18
ES2929137T3 (es) 2022-11-25
EP3412277A1 (en) 2018-12-12
SI2806855T1 (sl) 2018-11-30
JP6104282B2 (ja) 2017-03-29
SI3412277T1 (sl) 2023-03-31
EP3527198A1 (en) 2019-08-21
CN104080444B (zh) 2017-06-20
MX368199B (es) 2019-09-24
HUE060421T2 (hu) 2023-02-28
HK1200021A1 (en) 2015-07-31
RS63952B1 (sr) 2023-02-28
DK3412277T3 (da) 2023-02-20
DK3527199T3 (da) 2022-10-24
US20130189324A1 (en) 2013-07-25
JP2015508416A (ja) 2015-03-19
RS63706B1 (sr) 2022-11-30
LT3412277T (lt) 2023-04-25
DK3527197T3 (da) 2022-10-24
ES2929807T3 (es) 2022-12-01
PT3412277T (pt) 2023-02-14
PL3412277T3 (pl) 2023-06-19
LT3527197T (lt) 2022-11-25
PL3527196T3 (pl) 2022-11-21
PL3527199T3 (pl) 2022-12-12
AU2013211656B2 (en) 2017-07-13
HRP20230147T1 (hr) 2023-03-31
EP3020394A1 (en) 2016-05-18
WO2013110632A1 (en) 2013-08-01
PL3527197T3 (pl) 2022-11-21
CA2862548A1 (en) 2013-08-01
RS57637B1 (sr) 2018-11-30
ES2928688T3 (es) 2022-11-22
HRP20221431T1 (hr) 2023-01-06
EP3527199A1 (en) 2019-08-21
TW201334810A (zh) 2013-09-01
FI3412277T3 (fi) 2023-03-23
BR112014017481A2 (pt) 2017-06-13
NZ627837A (en) 2016-04-29
DK2806855T3 (en) 2018-09-03
EP3527197B1 (en) 2022-09-07
HUE060705T2 (hu) 2023-04-28
PL2806855T3 (pl) 2018-12-31
PE20141703A1 (es) 2014-11-24
TWI559940B (en) 2016-12-01
LT2806855T (lt) 2018-10-10
LT3527196T (lt) 2022-11-25
KR101786586B1 (ko) 2017-10-18
CA2862548C (en) 2020-07-07
KR101895279B1 (ko) 2018-09-05
MA35859B1 (fr) 2014-12-01
MX355729B (es) 2018-04-27
TN2014000322A1 (en) 2015-12-21
PT3527196T (pt) 2022-10-18
MY165888A (en) 2018-05-18
KR101560288B1 (ko) 2015-10-14
EP3527196A1 (en) 2019-08-21
ZA201405464B (en) 2015-12-23
HRP20221432T1 (hr) 2023-01-06
US10946029B2 (en) 2021-03-16
ES2938466T3 (es) 2023-04-11
PH12014501565A1 (en) 2014-10-08
IL233784A0 (en) 2014-09-30
DK3527198T3 (da) 2024-10-28
CN104080444A (zh) 2014-10-01
LT3527199T (lt) 2022-12-12
EP3527197A1 (en) 2019-08-21
CN105726548B (zh) 2019-05-14
EP2806855A1 (en) 2014-12-03
ES2683254T3 (es) 2018-09-25
RS63759B1 (sr) 2022-12-30
EP3527196B1 (en) 2022-09-07
EP3527198B1 (en) 2024-10-09
EP2806855B1 (en) 2018-07-11
US8778402B2 (en) 2014-07-15
AR089805A1 (es) 2014-09-17
US20180296573A1 (en) 2018-10-18
HRP20221433T1 (hr) 2023-01-06
HUE040525T2 (hu) 2019-03-28
HUE061566T2 (hu) 2023-07-28
AU2013211656A1 (en) 2014-07-24
CO7010836A2 (es) 2014-07-31
CL2014001966A1 (es) 2014-11-14

Similar Documents

Publication Publication Date Title
EA201491281A1 (ru) КОМПОЗИЦИЯ В ФОРМЕ СУХОГО ПОРОШКА, СОДЕРЖАЩАЯ КОРТИКОСТЕРОИД И β-АДРЕНЕРГИЧЕСКОЕ ЛЕКАРСТВЕННОЕ СРЕДСТВО, ДЛЯ ВВЕДЕНИЯ ИНГАЛЯЦИЕЙ
TN2015000278A1 (en) Autotaxin inhibitors
PH12015500274B1 (en) Alkylpyrimidine derivatives for the treatment of viral infections and further diseases
PH12016500094A1 (en) Autotaxin inhibitors
PH12016501139A1 (en) Bicyclic heterocycle compounds and their uses in therapy
JO3438B1 (ar) مركبات بنزين مستبدلة بأريل أو أريل غير متجانس
UA109464C2 (ru) Спироксиндольные антагонисты mdm2
GB201209613D0 (en) New compounds
MX346375B (es) Antagonistas de espiro-oxindol de mdm2.
GB201118656D0 (en) New compounds
EA201590667A1 (ru) Ациламинопиримидиновые производные для лечения вирусных инфекций и других заболеваний
MX349004B (es) Nuevos compuestos.
PH12014501514A1 (en) New azetidine derivatives, pharmaceutical compositions and uses thereof
MX2015004362A (es) Derivados de ketamina.
UA116889C2 (uk) Фармацевтична композиція, що містить суміш ізоформ apg101 (cd95-fc)
MX367926B (es) Composicion farmaceutica para liberacion sostenida de lanreotida.
EA201591415A1 (ru) Фармацевтические композиции, включающие многокомпонентные кристаллические частицы, подходящие для применения в ингаляционной терапии
MX359887B (es) Composicion masticable para administracion oral y proceso para preparar la misma.
EA201400444A1 (ru) Производные 2-оксопиперидинила
MX2016004094A (es) Composicion farmaceutica que comprende capecitabina y ciclofosfamida.
EA201491769A1 (ru) Фармацевтическая композиция с фиксированной дозой, содержащая мометазон и азеластин
MX2013002446A (es) Derivados de tetrahidropirrolopirazina sustituidos.
TN2013000202A1 (en) Spiro-oxindole mdm2 antagonists
TR201106224A2 (tr) Solunum yolu hastalıkları tedavisinde kullanılan farmasötik bileşimler.